Renalytix Plc (LON:RENX – Get Free Report) shares traded up 54.8% during trading on Monday . The company traded as high as GBX 8.90 ($0.12) and last traded at GBX 8.90 ($0.12). 3,460,224 shares were traded during trading, an increase of 1,700% from the average session volume of 192,234 shares. The stock had previously closed at GBX 5.75 ($0.08).
Renalytix Price Performance
The stock has a 50-day moving average price of GBX 6.60 and a 200 day moving average price of GBX 7.52. The company has a debt-to-equity ratio of -72.91, a current ratio of 0.24 and a quick ratio of 2.42. The firm has a market cap of £22.19 million, a price-to-earnings ratio of -41.88 and a beta of 2.10.
Renalytix Company Profile
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S.
Featured Articles
- Five stocks we like better than Renalytix
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Rezolute Stock: FDA Fast Track Fuels 2025 Breakout
- What is a support level?
- Is It Time to Trim Your Positions in These 2 AI Stocks?
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- These 3 Tech Stocks Just Supercharged Their Buybacks
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
